Online citations, reference lists, and bibliographies.

A Review Of The Novel Application And Potential Adverse Effects Of Proton Pump Inhibitors

Li-Yuan Yu, Lu-ning Sun, Xue-hui Zhang, Yue-qi Li, Lei Yu, Zi-Qing-Yun Yuan, Ling Meng, Hongwen Zhang, Yong-Qing Wang
Published 2017 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Proton pump inhibitors (PPIs) are known as a class of pharmaceutical agents that target H+/K+-ATPase, which is located in gastric parietal cells. PPIs are widely used in the treatment of gastric acid-related diseases including peptic ulcer disease, erosive esophagitis and gastroesophageal reflux disease, and so on. These drugs present an excellent safety profile and have become one of the most commonly prescribed drugs in primary and specialty care. Except for gastric acid-related diseases, PPIs can also be used in the treatment of Helicobacter pylori infection, viral infections, respiratory system diseases, cancer and so on. Although PPIs are mainly used short term in patients with peptic ulcer disease, nowadays these drugs are increasingly used long term, and frequently for a lifetime, for instance in patients with typical or atypical symptoms of gastroesophageal reflux disease and in NSAID or aspirin users at risk of gastrotoxicity and related complications including hemorrhage, perforation and gastric outlet obstruction. Long-term use of PPIs may lead to potential adverse effects, such as osteoporotic fracture, renal damage, infection (pneumonia and clostridium difficile infection), rhabdomyolysis, nutritional deficiencies (vitamin B12, magnesium and iron), anemia and thrombocytopenia. In this article, we will review some novel uses of PPIs in other fields and summarize the underlying adverse reactions.
This paper references
Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial
Jyh-Ming Liou (2013)
Effects of different proton pump inhibitors on cardiac contractility in isolated human failing myocardium.
Samuel Sossalla (2011)
selective activity against Helicobacter pylori
Retraction: Blockage of intracellular proton extrusion with proton pump inhibitor induces apoptosis in gastric cancer.
M. Yeo (2008)
The Association between the Use of Proton Pump Inhibitors and the Risk of Hypomagnesemia: A Systematic Review and Meta-Analysis
C. Park (2014)
Effect of esomeprazole versus placebo on pulmonary exacerbations in cystic fibrosis
Emily A Dimango (2014)
Proton Pump Inhibitor Usage and the Risk of Myocardial Infarction in the General Population
Nigam Haresh Shah (2015)
Treatment of Helicobacter pylori infection: Where are we now?
Jyh-Ming Liou (2016)
A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.
Andrew L Frelinger (2012)
Long-term proton pump inhibitor therapy and risk of hip fracture.
Yu-Xiao Yang (2006)
A combination of esomeprazole and aspirin reduces tissue concentrations of prostaglandin E(2) in patients with Barrett's esophagus.
Gary W. Falk (2012)
Modeling and simulation of the effect of proton pump inhibitors on magnesium homeostasis. 1. Oral absorption of magnesium.
J. Bai (2012)
Case report of proton pump inhibitor responsive esophageal eosinophilia: why 2 months of proton pump inhibitors is required.
Seth Lipka (2016)
Proton pump inhibitors enhance the effects of cytotoxic agents in chemoresistant epithelial ovarian carcinoma
Yoo-Young Lee (2015)
Role of mitochondrial permeability transition in human renal tubular epithelial cell death induced by aristolochic acid.
Xinming Qi (2007)
Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial.
M. B. O'Connell (2005)
Oligomycin, inhibitor of the F0 part of H+-ATP-synthase, suppresses the TNF-induced apoptosis
L. A. Shchepina (2002)
Discovery of a novel antitumor benzolactone enamide class that selectively inhibits mammalian vacuolar-type (H+)-atpases.
Michael R. Boyd (2001)
Stomaching calcium for bone health
Brendan F Boyce (2009)
Emergence of community-acquired Clostridium difficile infection: the experience of a French hospital and review of the literature.
M. Ogielska (2015)
Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial
K. Fukase (2008)
A randomized, single-blind study of lansoprazole for the prevention of exacerbations of chronic obstructive pulmonary disease in older patients.
T. Sasaki (2009)
Manipulating tumor acidification as a cancer treatment strategy.
Mark F. Mccarty (2010)
Use of Acid-Suppressive Drugs and Risk of Fracture: A Meta-analysis of Observational Studies
Chun-Sick Eom (2011)
'Lemonade Legs': Why do Some Patients Get Profound Hypomagnesaemia on Proton-Pump Inhibitors?
Nathan S. S. Atkinson (2015)
Proton Pump Inhibitors Inhibit Pancreatic Secretion: Role of Gastric and Non-Gastric H+/K+-ATPases
Jing Wang (2015)
Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori.
Javier P. Gisbert (2011)
Translating New Developments in Eosinophilic Esophagitis Pathogenesis into Clinical Practice
Edaire Cheng (2015)
A new strategy with proton pump inhibitors for the prevention of acute exacerbations in COPD
T. Sasaki (2011)
H+/K+-ATPase inhibitors: a patent review
Hao Li (2013)
Management of chronic obstructive pulmonary disease beyond the lungs.
Lowie Vanfleteren (2016)
Influence of efflux pump inhibitors on the multidrug resistance of Helicobacter pylori.
Zhan Zhang (2010)
Use of proton pump inhibitors and risk of osteoporosis-related fractures
L. Targownik (2008)
Hybrid therapy for Helicobacter pylori infection: A systemic review and meta-analysis.
Ping-I Hsu (2015)
Beyond gastric acid reduction: proton pump inhibitors induce heme oxygenase-1 in gastric and endothelial cells.
Jan Carl Becker (2006)
A Randomized Controlled Study Comparing Reverse Hybrid Therapy and Standard Triple Therapy for Helicobacter pylori Infection
Ping-I Hsu (2015)
Negative Inotropy of the Gastric Proton Pump Inhibitor Pantoprazole in Myocardium From Humans and Rabbits: Evaluation of Mechanisms
W. Schillinger (2007)
Influence of CYP2C19 on the relationship between pharmacokinetics and intragastric pH of omeprazole administered by successive intravenous infusions in Chinese healthy volunteers
Yongqing Wang (2010)
Growth inhibitory and bactericidal activities of lansoprazole compared with those of omeprazole and pantoprazole against Helicobacter pylori.
Masafumi Nakao (1998)
High dose lansoprazole combined with metronomic chemotherapy: a phase I/II study in companion animals with spontaneously occurring tumors
Enrico Pierluigi Spugnini (2014)
Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans.
C. Serfaty-Lacrosniere (1995)
Antimicrobial activity of esomeprazole versus omeprazole against Helicobacter pylori.
L Gatta (2003)
Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancer
Bi-yun Wang (2015)
Drug-Drug Interaction Profiles of Proton Pump Inhibitors
Ryuichi Ogawa (2010)
Review article: the long-term use of proton-pump inhibitors.
A. Raghunath (2005)
Proton pump inhibitors induce a caspase-independent antitumor effect against human multiple myeloma.
Andrea Canitano (2016)
First-line eradication for Helicobacter pylori-positive gastritis by esomeprazole-based triple therapy is influenced by CYP2C19 genotype.
Yoshimasa Saito (2015)
Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis
Chun-Sick Eom (2011)
Proton pump inhibitors: potential adverse effects
Neena S Abraham (2012)
Evaluating a physiologically based pharmacokinetic model for prediction of omeprazole clearance and assessing ethnic sensitivity in CYP2C19 metabolic pathway
S. Feng (2015)
Novel TOPK inhibitor HI-TOPK-032 effectively suppresses colon cancer growth.
D. Kim (2012)
Perils and pitfalls of long-term effects of proton pump inhibitors
Sheila M. Wilhelm (2013)
Proton pump inhibitors and the risk of acute kidney injury in older patients: a population-based cohort study.
T. Antoniou (2015)
Prognostic and predictive value of TOPK stratified by KRAS and BRAF gene alterations in sporadic, hereditary and metastatic colorectal cancer patients
I. Zlobec (2010)
Eosinophilic Esophagitis: An Evidence-Based Approach to Therapy.
Jesús González-Cervera (2016)
Pantoprazole-induced acute interstitial nephritis
Sheila Klassen (2013)
Study of the pharmacokinetics and intragastric pH of rabeprazole given as successive intravenous infusion to healthy Chinese volunteers
Yongqing Wang (2010)
Dose-dependent inhibitory effects of proton pump inhibitors on human osteoclastic and osteoblastic cell activity.
João Costa-Rodrigues (2013)
Systematic review with network meta-analysis: comparative effectiveness of topical steroids vs. PPIs for the treatment of the spectrum of eosinophilic oesophagitis.
S. Lipka (2016)
Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori.
T. Iwahi (1991)
The safety of drugs used in acid-related disorders and functional gastrointestinal disorders.
Neehar D. Parikh (2010)
A new look at anti-Helicobacter pylori therapy.
Seng-Kee Chuah (2011)
Extracellular acidification alters lysosomal trafficking in human breast cancer cells.
K. Glunde (2003)
Comparative risk of ischemic
CE Leonard
The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis
Angelo Zullo (2007)
Proton pump inhibitors induce apoptosis of human B-cell tumors through a caspase-independent mechanism involving reactive oxygen species.
A. de Milito (2007)
Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis
K. Filion (2013)
Omeprazole Inhibits Pancreatic Cancer Cell Invasion through a Nongenomic Aryl Hydrocarbon Receptor Pathway.
Un-Ho Jin (2015)
Proton Pump Inhibitors and Risk of Incident CKD and Progression to ESRD.
Yan Xie (2016)
TOPK inhibitor induces complete tumor regression in xenograft models of human cancer through inhibition of cytokinesis
Yo Matsuo (2014)
Optimal therapy for Helicobacter pylori infections
Emiko Rimbara (2011)
S Zhao (1998)
Hypomagnesemia and proton pump inhibitors: below the tip of the iceberg.
Tania W Furlanetto (2011)
Pantoprazole inhibits human gastric adenocarcinoma SGC-7901 cells by downregulating the expression of pyruvate kinase M2.
Yonghua Shen (2016)
Inventor method of using (H/K)ATPase inhibitors as antiviral agents
AEBDP Moormann (2005)
Diagnosis and treatment of eosinophilic esophagitis in clinical practice
Yasuhiko Abe (2017)
A Proton Pump Inhibitor’s Effect on Bone Metabolism Mediated by Osteoclast Action in Old Age: A Prospective Randomized Study
Yunju Jo (2015)
Hypomagnesaemia due to proton-pump inhibitor therapy: a clinical case series.
John Duncan Mackay (2010)
Effect of proton pump inhibitors on glycemic control in patients with diabetes.
Kohzo Takebayashi (2015)
A nationwide nested case-control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use
Mei-Ling Blank (2014)
Proton pump inhibition induces autophagy as a survival mechanism following oxidative stress in human melanoma cells
M. Marino (2010)
V-ATPase Inhibition Regulates Anoikis Resistance and Metastasis of Cancer Cells
Christina Maria Schempp (2014)
Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia.
Jennie Johnstone (2010)
Adverse Effects Associated With Proton Pump Inhibitors.
Adam J Schoenfeld (2016)
Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry
Jason S Long (2015)
Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry.
Jason S Long (2015)
Omeprazole Inhibits Proliferation and Modulates Autophagy in Pancreatic Cancer Cells
Andrej Udelnow (2011)
Comparative Risk of Ischemic Stroke Among Users of Clopidogrel Together With Individual Proton Pump Inhibitors
C. Leonard (2015)
Effect of Esomeprazole With/Without Acetylsalicylic Acid, Omeprazole and Lansoprazole on Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Volunteers
Tommy B. Andersson (2014)
Determinants of arterial stiffness in COPD
Surya P Bhatt (2014)
Modeling and simulation of the effect of proton pump inhibitors on magnesium homeostasis
JP Bai (2012)
Omeprazole inhibits colorectal carcinogenesis induced by azoxymethane in rats.
Ian D Penman (1993)
Intracellular apoptosis-inducing factor is induced by a vacuolar type H+-ATPase inhibitor in B lineage cells.
Shusuke Hashimoto (2001)
Randomized Controlled Trial Comparing 7-Day Triple, 10-Day Sequential, and 7-Day Concomitant Therapies for Helicobacter pylori Infection
P. Hsu (2014)
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
M. V. Vander Heiden (2009)
The proton pump inhibitor lansoprazole inhibits rhinovirus infection in cultured human tracheal epithelial cells.
T. Sasaki (2005)
Accumulating evidence for a drug-drug interaction between methotrexate and proton pump inhibitors.
Shewit Bezabeh (2012)
Pharmacokinetics of the new proton pump inhibitor ilaprazole in Chinese healthy subjects in relation to CYP3A5 and CYP2C19 genotypes.
Yalin Li (2008)
From hypomagnesaemia to Zollinger-Ellison syndrome: an adverse effect of a proton pump inhibitor
Allon Eyal (2014)
Gastroretentive drug delivery systems for the treatment of Helicobacter pylori.
Shan Zhao (2014)
Changes in the aetiology, clinical presentation and management of acute interstitial nephritis, an increasingly common cause of acute kidney injury.
Manuel Praga (2015)
Eosinophilic esophagitis that develops during therapy with proton pump inhibitors : case series and possible mechanisms.
Rok Orel (2016)
In Vitro Activities of Rabeprazole, a Novel Proton Pump Inhibitor, and Its Thioether Derivative Alone and in Combination with Other Antimicrobials against Recent Clinical Isolates ofHelicobacter pylori
Y. Kawakami (2000)
Blockage of intracellular proton extrusion with proton extrusions with proton pump inhibitor induces apoptosis in gastric cancer.
M. Yeo (2008)
Novel Application of Proton Pump Inhibitor for the Prevention of Colitis-Induced Colorectal Carcinogenesis beyond Acid Suppression
Y. Kim (2010)
Acute interstitial nephritis
D. Kleinknecht (1980)

This paper is referenced by
Effects of Calcium and Annatto Tocotrienol Supplementation on Bone Loss Induced by Pantoprazole in Male Rats
K. Chin (2020)
Sex-specific effects of Eugenia punicifolia extract on gastric ulcer healing in rats
Larissa Lucena Périco (2018)
Bowel symptoms in patients that receive proton pump inhibitors. Results of a multicenter survey in Mexico.
Max Schmulson (2019)
Hesperidin, a citrus flavanone glycoside, accelerates the gastric healing process of acetic acid-induced ulcer in rats.
Luísa Mota da Silva (2019)
Physiologic, pathophysiologic, and pharmacologic regulation of gastric acid secretion
Mitchell L. Schubert (2017)
Proton pump inhibitor intake negatively affects the osseointegration of dental implants: a retrospective study
Mehmet Ali Altay (2019)
Potentially inappropriate medications in hospitalized older patients: a cross-sectional study using the Beers 2015 criteria versus the 2012 criteria
Xiaolin Zhang (2017)
Proton Pump Inhibitors and Dementia: Physiopathological Mechanisms and Clinical Consequences
Gloria Ortiz-Guerrero (2018)
Proton pump inhibitors reduce breast cancer risk in gastric ulcer patients: A population-based cohort study.
Dah-Ching Ding (2019)
Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine
Nihal M. El Rouby (2018)
Treatment with proton pump inhibitors increases the risk for development of hepatic encephalopathy after implantation of transjugular intrahepatic portosystemic shunt (TIPS)
Lukas Sturm (2018)
Effects of Genetic Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Proton Pump Inhibitors.
He-Jian Zhang (2019)
Síntomas intestinales en pacientes que reciben inhibidores de bomba de protones (IBP). Resultados de una encuesta multicéntrica en México
Max Schmulson (2019)
Gastroprotective Value of Berries: Evidences from Methanolic Extracts of Morus nigra and Rubus niveus Fruits
Luciane Angela Nottar Nesello (2017)
Bowel symptoms in patients that receive proton pump inhibitors. Results of a multicenter survey in Mexico.
Max Schmulson (2019)
L’optimisation thérapeutique chez le sujet âgé en SSR : mise en œuvre et suivi en ville
Alicia Pic (2017)
Negative Association of Proton Pump Inhibitors With Subsequent Development of Breast Cancer: A Nationwide Population‐Based Study
Chao-hung Chen (2019)
The Effectiveness of Standard Single Dose Omeprazole vs. High Dose Continuous Infusion in High-risk Critically Ill Patients
Ezzeldin Ibrahim (2018)
Long Term Use of Proton Pump Inhibitors: Where to Draw the Line
Munirul M. Haque (2018)
Project IDentif.AI: Harnessing Artificial Intelligence to Rapidly Optimize Combination Therapy Development for Infectious Disease Intervention
Aynur Abdulla (2020)
Proton pump inhibitors for chronic obstructive pulmonary disease
Shino Kikuchi (2018)
Association of proton pump inhibitor use with renal outcomes in patients with coronary artery disease
Nam-jun Cho (2018)
The natural flavonoid myricetin inhibits gastric H+, K+‐ATPase
Yuu Miyazaki (2018)
Essential oil of Cymbopogon citratus (lemongrass) and geraniol, but not citral, promote gastric healing activity in mice.
Larissa Venzon (2018)
Anti-Gastric Ulcer Activity of Aqueous Extract of Terminalia Arjuna Against Helicobacter Pylori Lipopolysaccharide
Devi (2018)
The interaction between smoking, alcohol and the gut microbiome.
Gabriele Capurso (2017)
Pharmacodynamic interaction of 3α-hydroxymasticadienonic acid and diligustilide against indomethacin-induced gastric damage in rats.
Elizabeth Arlen Pineda-Peña (2019)
Increased risk of appendectomy in patients with gastroesophageal reflux disease
So Young Kim (2018)
Gastroprotective Effects of Paeonia Extract Mixture HT074 against Experimental Gastric Ulcers in Rats
Young-Sik Kim (2019)
The Use of Proton Pump Inhibitors May Increase Symptoms of Muscle Function Loss in Patients with Chronic Illnesses
Paulien Vinke (2020)
Schisantherin A induces cell apoptosis through ROS/JNK signaling pathway in human gastric cancer cells.
Zishu Wang (2019)
Safety, pharmacokinetics, and pharmacodynamics of S-(−)-pantoprazole sodium injections after single and multiple intravenous doses in healthy Chinese subjects
Hui-Wen Jiao (2017)
See more
Semantic Scholar Logo Some data provided by SemanticScholar